top of page

ATractiB

FIRST-LINE ATEZOLIZUMAB WITH PACLITAXEL AND BEVACIZUMAB FOR ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER

https://clinicaltrials.gov/study/NCT04408118

TNBC

28

100

II

Spain (and 4 other European countries)

Analysis

CLINICAL TRIAL DETAILS

THE ATRACTIB TRIAL IS A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY EVALUATING THE COMBINATION OF ATEZOLIZUMAB, PACLITAXEL AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER (aTNBC), INDEPENDENTLY OF PD-L1 STATUS. THE PRIMARY ENDPOINT WAS INVESTIGATOR-ASSESSED PROGRESSION-FREE SURVIVAL (PFS) BY RECIST V.1.1.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

home_fondo_you_barra.jpg

2023 Press Release: https://www.medsir.org/post/press-release-debbrah-cohort-5-and-atractib-trial-at-san-antonio-breast-cancer-symposium

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

Nature Medicine 2025 publication: https://www.nature.com/articles/s41591-025-03734-3 | AACR 2024 abstract: https://aacrjournals.org/cancerres/article/84/9_Supplement/PS16-02/743813/Abstract-PS16-02-Efficacy-and-safety-of-first-line

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

MEDSIR presents promising results at SABCS 2023: ATRACTIB and DEBBRAH trials hold potential to improve the lives of advanced breast cancer patients: https://www.prnewswire.com/news-releases/medsir-presents-promising-results-at-sabcs-2023-atractib-and-debbrah-trials-hold-potential-to-improve-the-lives-of-advanced-breast-cancer-patients-302008852.html

PHERGAIN SITES

home_fondo_you_barra.jpg
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page